Latest Tax Incentives News

Right Resources posted a A$5.16 million loss for FY2026 and warned of material uncertainty over its ability to continue as a going concern, despite A$3.24 million in cash at year-end and a subsequent A$2.94 million capital raise. The explorer is betting that new drilling at Blue and a revised geological model at Pilot can improve the investment case.

Wildcat Resources has entered FY27 with a $60 million placement, a $37.2 million year-end cash balance and its Tabba Tabba lithium project advancing towards a definitive feasibility study. The funding strengthens the development runway, but final investment approval, financing and approvals remain ahead.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.

IODM Limited (ASX:IOD) increased FY2026 revenue by 16.9% and narrowed its net loss, but auditors flagged material uncertainty over the company’s ability to continue as a going concern. A post-year-end A$1.00 million placement is funding an expansion into North American universities while the business remains heavily reliant on external capital.

Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.

Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.

AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

Eastern Gas has signed a non-binding term sheet for up to A$10 million in R&D-backed debt, including an initial drawdown of up to A$1.5 million. The proposed funding comes with 9% interest, multiple fees, options and security over future R&D rebates.

Murray Cod Australia posted a $5.37 million FY2026 loss after the prior year’s $8.56 million profit, despite higher fish biomass and improved fourth-quarter performance. The company ended the year with $4.14 million in cash after raising capital, while operating cash outflow reached $26.57 million and a Westpac interest-cover covenant was breached and waived.

BluGlass has agreed an A$8.0 million R&D-backed loan with Rockford, refinancing its existing Radium facility and adding about A$5.5 million of liquidity. The funding gives the laser developer more room to scale, but carries a 16.5% interest rate and repayment obligations tied to future tax refunds.